Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma

Masatoshi Sakurai, Daiki Karigane, Hidenori Kasahara, Tomohiko Tanigawa, Akaru Ishida, Hiroshi Murakami, Masao Kikuchi, Sumiko Kohashi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The proportion of elderly patients with diffuse large B cell lymphoma (DLBCL) appears to be increasing, with outcomes varying widely because of the patients’ heterogeneity. Geriatric assessment is used to predict prognosis in elderly patients with DLBCL, but the utility of two simple screening tools for patients with DLBCL, the Flemish version of the Triage Risk Screening Tool (fTRST) and G8, has remained to be elucidated. We retrospectively assessed patients using fTRST and G8, and evaluated the impacts of the scores on survival outcomes in older patients with newly diagnosed DLBCL. A total of 59 patients aged 65 years or older and who were diagnosed with DLBCL were included. The median age was 77 years (range, 65–91 years), and the initial treatments were R-CHOP (63%) and R-THPCOP (31%). The estimated 2-year overall survival (OS) rate was significantly lower in patients with abnormal fTRST scores (≥ 2; N = 17) than in those with normal fTRST scores (< 2; N = 42): (50.5% (95% CI, 22.7–73.0%) vs. 82.2% (95% CI, 63.8–91.8%), P = 0.007). The estimated 2-year OS rate was significantly lower also in patients with abnormal G8 scores (≤ 14; N = 38) than in those with normal G8 scores (> 14; N = 21): (66.1% (95% CI, 46.7–79.5%) vs. 86.8% (95% CI, 55.7–96.7%), P = 0.03, respectively). These associations were independently significant after adjusting for other significant factors by multivariate analysis. These results suggest that the easy-to-use geriatric screening tools, fTRST and G8, have strong prognostic value for OS in older patients with DLBCL.

Original languageEnglish
Pages (from-to)669-678
Number of pages10
JournalAnnals of Hematology
Volume98
Issue number3
DOIs
Publication statusPublished - 2019 Mar 4
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Geriatrics
Triage
Survival
Geriatric Assessment
Statistical Factor Analysis
Multivariate Analysis
Survival Rate

Keywords

  • Diffuse large B cell lymphoma
  • Geriatric screening tools
  • Older patients
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma. / Sakurai, Masatoshi; Karigane, Daiki; Kasahara, Hidenori; Tanigawa, Tomohiko; Ishida, Akaru; Murakami, Hiroshi; Kikuchi, Masao; Kohashi, Sumiko.

In: Annals of Hematology, Vol. 98, No. 3, 04.03.2019, p. 669-678.

Research output: Contribution to journalArticle

Sakurai, M, Karigane, D, Kasahara, H, Tanigawa, T, Ishida, A, Murakami, H, Kikuchi, M & Kohashi, S 2019, 'Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma', Annals of Hematology, vol. 98, no. 3, pp. 669-678. https://doi.org/10.1007/s00277-018-3551-y
Sakurai, Masatoshi ; Karigane, Daiki ; Kasahara, Hidenori ; Tanigawa, Tomohiko ; Ishida, Akaru ; Murakami, Hiroshi ; Kikuchi, Masao ; Kohashi, Sumiko. / Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma. In: Annals of Hematology. 2019 ; Vol. 98, No. 3. pp. 669-678.
@article{7fa43603319141e0ae121477f25a246f,
title = "Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma",
abstract = "The proportion of elderly patients with diffuse large B cell lymphoma (DLBCL) appears to be increasing, with outcomes varying widely because of the patients’ heterogeneity. Geriatric assessment is used to predict prognosis in elderly patients with DLBCL, but the utility of two simple screening tools for patients with DLBCL, the Flemish version of the Triage Risk Screening Tool (fTRST) and G8, has remained to be elucidated. We retrospectively assessed patients using fTRST and G8, and evaluated the impacts of the scores on survival outcomes in older patients with newly diagnosed DLBCL. A total of 59 patients aged 65 years or older and who were diagnosed with DLBCL were included. The median age was 77 years (range, 65–91 years), and the initial treatments were R-CHOP (63{\%}) and R-THPCOP (31{\%}). The estimated 2-year overall survival (OS) rate was significantly lower in patients with abnormal fTRST scores (≥ 2; N = 17) than in those with normal fTRST scores (< 2; N = 42): (50.5{\%} (95{\%} CI, 22.7–73.0{\%}) vs. 82.2{\%} (95{\%} CI, 63.8–91.8{\%}), P = 0.007). The estimated 2-year OS rate was significantly lower also in patients with abnormal G8 scores (≤ 14; N = 38) than in those with normal G8 scores (> 14; N = 21): (66.1{\%} (95{\%} CI, 46.7–79.5{\%}) vs. 86.8{\%} (95{\%} CI, 55.7–96.7{\%}), P = 0.03, respectively). These associations were independently significant after adjusting for other significant factors by multivariate analysis. These results suggest that the easy-to-use geriatric screening tools, fTRST and G8, have strong prognostic value for OS in older patients with DLBCL.",
keywords = "Diffuse large B cell lymphoma, Geriatric screening tools, Older patients, Prognosis",
author = "Masatoshi Sakurai and Daiki Karigane and Hidenori Kasahara and Tomohiko Tanigawa and Akaru Ishida and Hiroshi Murakami and Masao Kikuchi and Sumiko Kohashi",
year = "2019",
month = "3",
day = "4",
doi = "10.1007/s00277-018-3551-y",
language = "English",
volume = "98",
pages = "669--678",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma

AU - Sakurai, Masatoshi

AU - Karigane, Daiki

AU - Kasahara, Hidenori

AU - Tanigawa, Tomohiko

AU - Ishida, Akaru

AU - Murakami, Hiroshi

AU - Kikuchi, Masao

AU - Kohashi, Sumiko

PY - 2019/3/4

Y1 - 2019/3/4

N2 - The proportion of elderly patients with diffuse large B cell lymphoma (DLBCL) appears to be increasing, with outcomes varying widely because of the patients’ heterogeneity. Geriatric assessment is used to predict prognosis in elderly patients with DLBCL, but the utility of two simple screening tools for patients with DLBCL, the Flemish version of the Triage Risk Screening Tool (fTRST) and G8, has remained to be elucidated. We retrospectively assessed patients using fTRST and G8, and evaluated the impacts of the scores on survival outcomes in older patients with newly diagnosed DLBCL. A total of 59 patients aged 65 years or older and who were diagnosed with DLBCL were included. The median age was 77 years (range, 65–91 years), and the initial treatments were R-CHOP (63%) and R-THPCOP (31%). The estimated 2-year overall survival (OS) rate was significantly lower in patients with abnormal fTRST scores (≥ 2; N = 17) than in those with normal fTRST scores (< 2; N = 42): (50.5% (95% CI, 22.7–73.0%) vs. 82.2% (95% CI, 63.8–91.8%), P = 0.007). The estimated 2-year OS rate was significantly lower also in patients with abnormal G8 scores (≤ 14; N = 38) than in those with normal G8 scores (> 14; N = 21): (66.1% (95% CI, 46.7–79.5%) vs. 86.8% (95% CI, 55.7–96.7%), P = 0.03, respectively). These associations were independently significant after adjusting for other significant factors by multivariate analysis. These results suggest that the easy-to-use geriatric screening tools, fTRST and G8, have strong prognostic value for OS in older patients with DLBCL.

AB - The proportion of elderly patients with diffuse large B cell lymphoma (DLBCL) appears to be increasing, with outcomes varying widely because of the patients’ heterogeneity. Geriatric assessment is used to predict prognosis in elderly patients with DLBCL, but the utility of two simple screening tools for patients with DLBCL, the Flemish version of the Triage Risk Screening Tool (fTRST) and G8, has remained to be elucidated. We retrospectively assessed patients using fTRST and G8, and evaluated the impacts of the scores on survival outcomes in older patients with newly diagnosed DLBCL. A total of 59 patients aged 65 years or older and who were diagnosed with DLBCL were included. The median age was 77 years (range, 65–91 years), and the initial treatments were R-CHOP (63%) and R-THPCOP (31%). The estimated 2-year overall survival (OS) rate was significantly lower in patients with abnormal fTRST scores (≥ 2; N = 17) than in those with normal fTRST scores (< 2; N = 42): (50.5% (95% CI, 22.7–73.0%) vs. 82.2% (95% CI, 63.8–91.8%), P = 0.007). The estimated 2-year OS rate was significantly lower also in patients with abnormal G8 scores (≤ 14; N = 38) than in those with normal G8 scores (> 14; N = 21): (66.1% (95% CI, 46.7–79.5%) vs. 86.8% (95% CI, 55.7–96.7%), P = 0.03, respectively). These associations were independently significant after adjusting for other significant factors by multivariate analysis. These results suggest that the easy-to-use geriatric screening tools, fTRST and G8, have strong prognostic value for OS in older patients with DLBCL.

KW - Diffuse large B cell lymphoma

KW - Geriatric screening tools

KW - Older patients

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85056662656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056662656&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3551-y

DO - 10.1007/s00277-018-3551-y

M3 - Article

C2 - 30443764

AN - SCOPUS:85056662656

VL - 98

SP - 669

EP - 678

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 3

ER -